THE RESEARCH
TEAM.
The editorial collective behind chronic-illness.st research content - who we are, what we cover, and how we source.
The Chronic Illness Research Team is the editorial collective responsible for the research-context content published on chronic-illness.st. The team operates as a distributed curation effort - reading primary literature, tracking research-community discourse, and synthesising the current state of knowledge on thyroid hormones, deiodinase biology, the Wilson's Temperature Syndrome framework, and the T3 to T2 conversion problem. All content is produced collectively, attributed to the team entity rather than individual contributors.
By design, the team does not include licensed medical professionals operating in a clinical advisory capacity. The content published here is research curation - not clinical guidance, not treatment recommendation. Compounds discussed and sold on this site are strictly for laboratory research use. Operating without individual licensed-medical-professional bylines is a deliberate choice that reflects the nature of the content: we are cataloguing and contextualising peer-reviewed research, not providing clinical opinions. That framing is consistent across every post, every product page, and every annotation on this site.
What We Cover
Our topical coverage maps directly to the research areas most relevant to the compounds sold on this site and the chronic-illness research community that uses them. The following areas represent our editorial scope:
- Slow-release T3 (liothyronine) pharmacokinetics - absorption curves, half-life variability, and compounding considerations
- Wilson's Temperature Syndrome - the clinical hypothesis, the basal temperature protocol, and its positioning relative to mainstream endocrinology
- The WT3 cyclic protocol - dosing cadence, ramp-and-taper logic, and the research literature underlying it
- Reverse T3 dominance - mechanisms of rT3 accumulation, the FT3:rT3 ratio, and hypotheses on its clinical significance
- The T3 to T2 conversion problem - why peripheral deiodination efficiency matters and what the research literature says about it
- 3,5-T2 (3,5-diiodo-L-thyronine) - mitochondrial biology, UCP1 activation hypotheses, and emerging research directions
- Deiodinase enzymology (DIO1, DIO2, DIO3) - substrate specificity, tissue distribution, and regulatory genetics
- Thyroid hormone receptor biology - TR-alpha vs TR-beta isoforms, nuclear receptor signalling, and bioenergetic implications
- Sustained-release vs immediate-release thyroid hormone formulations - pharmacokinetic tradeoffs in research contexts
- Bioenergetic framings of chronic-illness presentations - mitochondrial dysfunction hypotheses, ATP synthesis efficiency, and related research literature
- Peptide adjuncts to thyroid research - compounds studied alongside T3 protocols in the research community
- HPLC purity verification methodology - how to interpret Certificates of Analysis and what third-party lab verification covers
- Customs and international shipping of research compounds - regulatory landscape, declaration obligations, and jurisdiction-specific context
How We Source
The primary sources for all clinical-shape claims are peer-reviewed publications indexed on PubMed and PubMed Central (PMC). Where a claim concerns a mechanism - receptor binding affinity, deiodinase substrate specificity, pharmacokinetic modelling - we cite the specific primary literature rather than review articles alone. Where a claim originates in research-community discussion rather than formal publication (investigator forum posts, primary investigator presentations, grey-literature protocols), we label it explicitly as research-community hypothesis and distinguish it from established mechanism.
Every YMYL post carries a bibliography in its frontmatter and on-page citation list. We separate three epistemic tiers inside our content: “established mechanism” (primary literature consensus), “research-community hypothesis” (investigator speculation with plausible mechanistic basis), and “not endorsed by mainstream endocrinology” (frameworks such as Wilson's Temperature Syndrome that sit outside conventional clinical practice). The full sourcing process is described in our Editorial Methodology.
What We Are Not
The Chronic Illness Research Team is not a medical practice, a clinic, or a regulatory-approved health authority. Nothing published on chronic-illness.st constitutes clinical advice, diagnosis, or treatment recommendation. All compounds sold on this site are offered strictly for laboratory research use - they are not pharmaceutical products approved for human consumption, and they are not sold with any clinical indication. Researchers are responsible for complying with the laws and regulations of their jurisdiction regarding the acquisition and use of research compounds. For the full legal terms governing our products, see our FAQ.
How to Reach Us
Editorial questions, factual corrections, and citation disputes can be submitted via our contact page. If you believe a claim in one of our posts is inaccurate or that a cited source has been retracted or superseded, please include the post URL, the specific claim, and the corrective source. Material corrections are published with a dated update note on the original post. We review and respond to substantive correction requests within 14 days.